Health Care • Medical/Dental Instruments
$2.31 ▼ -0.05
(-2.12%)
MKT CAP: $3.8M • VOL: 16.5K
52W L $2 52W H $53
ROARABLE / RQD
D- • 42/100
PIOTROSKI
3 / 9
XAIR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-03-31 | FY 2024
FILED 2025-03-31 | FY 2023
FILED 2024-03-31 |
|---|---|---|---|
| Revenue (Total Sales) | $7.7M | $3.7M | $1.2M |
| YoY Revenue Growth % | +107.3% | +219.7% | — |
| Gross Profit | $252.0K | -$1.7M | — |
| Gross Margin % | 3.3% | -44.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$29.0M | -$44.5M | -$63.0M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | $34.3K | $48.5K | $64.3K |
| EBITDA (Normalized) | -$28.2M | -$39.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$18.1M | -$38.2M | -$56.0M |
| Capital Expenditures (CapEx) | $1.0M | $5.9M | — |
| Free Cash Flow (FCF) | -$19.2M | -$44.1M | -$56.0M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $6.6M | $4.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $8.1M | $17.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR XAIR.